A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolamide, interferon alfa, and interleukin-2 for metastatic melanoma

7567 Background: Evaluation of antitumor activity and toxicity of concurrent biochemotherapy that uses cisplatin, vinblastine, temozolamide (Temodal), interferon alfa-2a (IFN-alfa), and interleukin-2 (IL-2) in patients with metastatic melanoma. Methods: Between May 2001 and May 2003, 22 patients with a documented diagnosis of metastatic melanoma with measurable lesions and an Eastern Oncology Cooperative Group (ECOG) performance status of 2 or less were enrolled in this study. Patients were required to have no clinically significant cardiac dysfunction and to be free from symptomatic brain metastases. The treatment consisted of cisplatin 20 mg/m2 daily for 4 days, vinblastine 1.6 mg/m2 daily for 4 days, and oral temozolamide 250 mg/m2 for 5 days, with IL-2 18 × 106 IU/m2 IV decrescendo half dose daily by continuous infusion for 4 days, and IFN-alfa 5 × 106 U/m2 subcutaneously daily for 5 days, repeated at 28-day intervals. Response was assessed after two or three cycles and patients who responded were con...